Find trending articles through Social News Discovery®! Providing a collaboration of news through social media technologies.
Follow your friends and create your own Online Social Newspaper! Invite your friends to follow you from Facebook. Filter the news articles you see by section, clipper, or mood. Rate each article and comment on all news clips!
Receive site and email notifications about comments and news clips that you are collaborating on!
Get the latest news on the Everyone page, the viral and trending news clips will always be at the top! See the trending news and articles!
"Following release in March of positive topline results from a phase 3 trial of an investigational cannabidiol product (Epidiolex, GW Pharmaceuticals) in patients with Dravet syndrome, GW Pharmaceuticals has now announced more positive results, this time from a phase 3 study in patients with Lennox-G...", www.weedhorn.com
"Cambridge UK cannabis-based medical business GW Pharmaceuticals enjoyed a 12 per cent hike in its share price on the back of results from a key phase 3 paediatric epilepsy trial. It was the second major trial of GW’s Epidiolex® treatment to combat seizures in epileptic children suffering from Lennox-Gastaut syndrome. CEO Justin Gover (pictured) said the product achieved its primary endpoint with high statistical significance.", www.businessweekly.co.uk
"GW Pharmaceuticals' cannabinoid Epidiolex continues to impress in late-stage clinical trials, with a Phase III study involving patients with Lennox-Gastaut syndrome - a rare and severe form of childhood-onset epilepsy - the latest to hit its targets. - News - PharmaTimes", www.pharmatimes.com
"Positive results have been reported from a phase 3, randomized, double-blind, placebo-controlled study of the investigational medication Epidiolex (cannabidiol, GW Pharmaceuticals) in the treatment of patients with Lennox–Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In this study, Epidiolex, when added as an adjunct to the patient’s current treatment, achieved the primary endpoint of a significant reduction in the monthly frequency of drop seizures assessed over the 14-week treatment period compared with placebo (P = 0.0135).", www.ptcommunity.com
"Positive results have been reported from a phase 3, randomized, double-blind, placebo-controlled study of the investigational medication Epidiolex (cannabidiol, GW Pharmaceuticals) in the treatment of patients with Lennox–Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.", www.managedcaremag.com
Please enjoy the site during our beta phase and provide us with feedback on suggestions and issue details. Please remember that we are still in beta and there will be issues and site changes during this time.
Newsclip® the leading Online Social Newspaper, find trending articles through Social News Discovery®!
You can reopen the "Getting Started Tutorial" dialog from within the About menu in the top right corner.